Innovaccer Inc. announced it has improved its integration with athenahealth through the company’s Marketplace program, making it easier for joint customers to access important analytics while streamlining clinical workflows and accelerating value realization. Innovaccer’s new integration with athenahealth’s Data View solution and EHR write-back functionality allows healthcare organizations to access clinical, financial, and scheduling data and reduce administrative burden. The integration aims to decrease the onboarding and go live timeline for Innovaccer’s solutions to as little as one to two weeks.
Health Technology Insights: Star Health Insurance Wins “Best Health Insurance Company” at InsureNext 2025
The enhanced EHR write-back functionality enables bidirectional data exchange between Innovaccer’s systems and athenaOne, eliminating the need for physicians to toggle between multiple screens. With real-time data synchronization and automated documentation, providers can focus more on patient care while maintaining complete, accurate records in their EHR. This streamlined approach not only saves valuable physician time but can also enhance care quality by ensuring instant access to updated patient information at the point of care.
Health Technology Insights: IHS, LLC Acquires BC Healthcare Practice to Expand Services & Improve Patient Care
Organizations choosing Innovaccer’s connection to Data View will benefit from reduced activation and monthly costs. Daily data refresh cycles ensure analytics and reporting remain current, establishing a robust foundation for value-based care initiatives and improved business outcomes.
“This partnership represents a significant advancement in healthcare data integration,” said Abhinav Shashank, cofounder and CEO of Innovaccer. “By leveraging athenahealth’s Data View capabilities and enhancing our EHR write-back functionality, we’re helping athenahealth customers realize value faster through streamlined data access, improved analytics, and automated workflows—all while significantly reducing implementation time and costs.”
Health Technology Insights: U.S. FDA Approves Expanded Label for Astellas’ IZERVAY for Geographic Atrophy
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source: Businesswire
